Medicare drug benefit annual enrollment

1 December 2008

The annual Medicare Part D prescription drug benefit enrollment process has opened from November 15 to December 31, with the now yearly ritual of conflicting claims about costs, an allegedly "confusing" number of private plans for senior citizens to choose from and questions about the infamous "Donut hole" coverage gap (Marketletters passim). The Drugsite Trust, a group that operates the popular drugs.com web site, has launched its own Part D plan selector tool, which competes with the Centers for Medicare and Medicaid Services' (CMS) own www.medicare.gov service. The Drugs.com guide aims to locate the most cost-effective provider based on location and which medicines are prescribed.

For 2009, the Donut hole will apply for beneficiaries' prescription medicines spending of between $2,700 and $4,350. Beyond that point, "catastrophic coverage" means that the provider is responsible for paying most drug costs, with a co-payment of $6 for branded and $2.40 for generic drugs.

This article is accessible to registered users, to continue reading please register for free.  A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Login to your account

Become a subscriber

 

£820

Or £77 per month

Subscribe Now
  • Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
  • Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
  • Daily roundup of key events in pharma and biotech.
  • Monthly in-depth briefings on Boardroom appointments and M&A news.
  • Choose from a cost-effective annual package or a flexible monthly subscription
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK





Today's issue

Company Spotlight